Vivos Therapeutics Inc Stock News

LITTLETON, Colo., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders, including obstructive sleep apnea (OSA), today released previously unpublished clinical dat...

LITTLETON, Colo., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders, including obstructive sleep apnea (OSA), today announced first time, peer-reviewed publishe...

Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q2 2025 Earnings Conference Call August 19, 2025 5:00 PM ET Company Participants Bradford K. Amman - CFO, Treasurer & Secretary R.

Quarter highlighted by the key acquisition of The Sleep Center of Nevada, which is generating revenue and seeing strong patient demand for Vivos' differentiated array of  highly effective OSA treatments Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical ...

LITTLETON, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe O...

LITTLETON, Colo., June 26, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leader in proprietary, non-invasive treatments for obstructive sleep apnea (OSA), today announced that the European Journal of Pediatrics has published the results of a groundbreaking multicenter clinical trial evidencing positive results for the treatment of OSA in children...

Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q1 2025 Earnings Conference Call May 15, 2025 5:00 PM ET Company Participants Brad Amman - CFO Kirk Huntsman - Chairman and CEO Conference Call Participants Do Kim - Water Tower Research Lucas Ward - Ascendiant Capital Markets Operator Good day, everyone. And welcome to the Vivos Therapeutics First Quarter 2025 Earnings Call.

LITTLETON, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate t...